📚 Part of the TILA-278 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.
This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.
What it is. Module 4.3 — Literature References (TILA-278)
Why it exists. Animal pharmacology, PK, and toxicology supporting the safety of clinical dosing.
How it is produced here. No real animal studies were run for this portfolio, so this is deep-knowledge mock: the study designs, endpoints, and conclusions are realistic domain content standing in for real laboratory data.
Format & governing standard. —
Document ID: M43
Version: 1.0
Change History: 1.0 — Initial issue.
Standard(s): ICH M4S
The published nonclinical literature cited across Module 4 for TILA-278 (bispecific monoclonal antibody): mechanism/class pharmacology, the cynomolgus monkey as the sole pharmacologically relevant species (no rodent cross-reactivity) model, and the toxicology of the target pathway. Full citations accompany each Module 4 report.
No comments yet. Be the first to say something!